The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

Last May, the Food and Drug Administration (FDA) approved the company's second product, a vaccine for respiratory syncytial ...

Abrysvo, which is now the first maternal RSV vaccine to be prequalified by the organisation, aims to prevent RSV-associated ...

A single dose of respiratory syncytial virus vaccine was effective against infections and associated hospitalizations in veterans aged at least 60 years during the 2023-24 season.

On 12 March 2025, the World Health Organization (WHO) prequalified the first maternal respiratory syncytial virus (RSV) vaccine to protect infants ...

Moderna (MRNA) announced that the Medicines and Healthcare products ... active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults ...

"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna.

CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products ... authorization of our RSV vaccine is an important ...